Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial - PubMed
5 hours ago
- #CIDP
- #IVIg
- #clinical trial
- The study investigated the efficacy of intravenous methylprednisolone (IVMP) as an add-on to intravenous immunoglobulin (IVIg) for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- A randomized, double-blind, placebo-controlled trial was conducted with 77 participants (out of a planned 96) due to safety concerns, including four thromboembolic events in the IVIg/IVMP group.
- At 52 weeks, 38% of participants in the IVIg/IVMP group achieved remission compared to 28% in the IVIg/placebo group, but the difference was not statistically significant (p=0.47).
- Secondary outcomes showed greater improvement in disability and impairment in the IVIg/IVMP group at 18 and 52 weeks.
- The study was prematurely stopped due to safety concerns, and combined treatment did not significantly increase remission rates compared to IVIg alone.
- Several authors reported conflicts of interest, including receiving honoraria, advisory board memberships, and research grants from pharmaceutical companies.